Fosrenol (Lanthanum Carbonate) Patent Expiration, LOE Window & CMS Spending

Fosrenol (Lanthanum Carbonate) by Takeda: FDA Orange Book LOE 2030-12-01, 4 AB generics, $6.5M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTakeda
FDA Application & PathwayN021468 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2030-12-01
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$6.5M
2024 Medicare Part D Spend$5.3M
2024 Medicaid Spend$1.2M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Takeda across sibling Meru public-data platforms.